Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + aBFM in Newly Diagnosed T-ALL and T-LL
NCT07072585Phase 3Not yet recruiting
- Sponsor
- Children's Oncology Group
- Start
- Aug 2026
- Primary completion
- Sep 2035
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 3 trial of daratumumab in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), sponsored by Children's Oncology Group. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
daratumumab
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT07072585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07072585.